As poor economic conditions continue to buffet the biopharma sector, tool vendors, especially publicly traded ones, have had to trim spending, cut staff, and lower expectations. Consequently, these steps have presented challenging questions to investors, R&D partners, and potential collaborators:
How does one company’s overall health compare with its competitors? Is it the right time to approach one firm over another for an R&D partnership? Will one collaboration stay on track or stall?